Published in BMC Cancer on April 12, 2014
Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget (2015) 0.94
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer (2015) 0.79
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget (2015) 0.78
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Rep (2017) 0.75
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer (2016) 0.75
Tumor-induced Stromal STAT1 Accelerates Breast Cancer via Deregulating Tissue Homeostasis. Mol Cancer Res (2017) 0.75
Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget (2016) 0.75
Systematic drug perturbations on cancer cells reveal diverse exit paths from proliferative state. Oncotarget (2016) 0.75
IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer Lett (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33
Genesis: cluster analysis of microarray data. Bioinformatics (2002) 10.50
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol (2007) 6.89
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
Serine phosphorylation of STATs. Oncogene (2000) 4.21
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J (1996) 2.50
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol (2011) 2.38
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer (2012) 2.16
Gene modulation and immunoregulatory roles of interferon gamma. Cytokine (2009) 2.12
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
STAT1 as a key modulator of cell death. Cell Signal (2006) 1.85
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle (2011) 1.79
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A (2009) 1.78
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat (2008) 1.60
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
CXCL10 and autoimmune diseases. Autoimmun Rev (2008) 1.49
The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2010) 1.48
Replenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1. J Leukoc Biol (2013) 1.44
Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res (2006) 1.43
STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One (2009) 1.37
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res (2012) 1.29
CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity (2013) 1.28
Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia (2010) 1.23
STAT1 and pathogens, not a friendly relationship. Biochimie (2010) 1.23
STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol (2008) 1.12
Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem (2013) 1.06
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 1.02
The tumor suppressor function of STAT1 in breast cancer. JAKSTAT (2013) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Selective response to insulin versus insulin-like growth factor-I and -II and up-regulation of insulin receptor splice variant B in the differentiated mouse mammary epithelium. Endocrinology (2009) 0.93
Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget (2011) 0.92
Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat (2001) 0.91
Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol (2009) 0.91
The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol (2007) 0.91
Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res (2012) 0.90
Interferon-induced antiviral protein MxA interacts with the cellular RNA helicases UAP56 and URH49. J Biol Chem (2011) 0.90
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol (2009) 0.89
Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gamma signaling. Proc Natl Acad Sci U S A (2009) 0.88
Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol (2003) 0.85
Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection. FASEB J (2009) 0.81
Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells. Clin Breast Cancer (2013) 0.80
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Genesis: cluster analysis of microarray data. Bioinformatics (2002) 10.50
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform (2013) 3.60
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res (2006) 2.93
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell (2010) 2.31
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 2.26
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
MARS: microarray analysis, retrieval, and storage system. BMC Bioinformatics (2005) 2.14
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
PathwayExplorer: web service for visualizing high-throughput expression data on biological pathways. Nucleic Acids Res (2005) 2.12
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics (2007) 1.90
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology (2011) 1.56
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol (2011) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
Proteomic profiling of acute cardiac allograft rejection. Transplantation (2009) 1.44
Estradiol enhances murine cardiac allograft rejection under cyclosporin and can be antagonized by the antiestrogen tamoxifen. Transplantation (2002) 1.44
Tetrahydrobiopterin protects the kidney from ischemia-reperfusion injury. Kidney Int (2010) 1.41
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays. Nucleic Acids Res (2009) 1.37
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol (2015) 1.35
MASPECTRAS: a platform for management and analysis of proteomics LC-MS/MS data. BMC Bioinformatics (2007) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells (2008) 1.32
Activin a plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes (2010) 1.31
25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem (2004) 1.30
YPL.db: the Yeast Protein Localization database. Nucleic Acids Res (2002) 1.26
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol (2004) 1.26
SIMPLEX: cloud-enabled pipeline for the comprehensive analysis of exome sequencing data. PLoS One (2012) 1.22
A quantization method based on threshold optimization for microarray short time series. BMC Bioinformatics (2005) 1.21
Mutations in ROGDI Cause Kohlschütter-Tönz Syndrome. Am J Hum Genet (2012) 1.21
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
Generic features of tertiary chromatin structure as detected in natural chromosomes. Mol Cell Biol (2004) 1.19
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ®-labelled specimens. J Proteomics (2010) 1.18
Molecular processes during fat cell development revealed by gene expression profiling and functional annotation. Genome Biol (2005) 1.16
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet (2011) 1.16
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol (2006) 1.16
14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res (2005) 1.15
TAMEE: data management and analysis for tissue microarrays. BMC Bioinformatics (2007) 1.15
New trends in bioinformatics: from genome sequence to personalized medicine. Exp Gerontol (2003) 1.15
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A (2010) 1.15
iLAP: a workflow-driven software for experimental protocol development, data acquisition and analysis. BMC Bioinformatics (2009) 1.14
Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer (2002) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Comparative transcriptomics of human multipotent stem cells during adipogenesis and osteoblastogenesis. BMC Genomics (2008) 1.09
Identification of evolutionarily conserved genetic regulators of cellular aging. Aging Cell (2010) 1.09
Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression. BMC Mol Biol (2010) 1.09
Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice. Genomics (2008) 1.07
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
QPCR: Application for real-time PCR data management and analysis. BMC Bioinformatics (2009) 1.04
Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. EMBO J (2003) 1.04
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res (2014) 1.04